Diagnostic methods used in searching for markers of atrophy in patients with multiple sclerosis. (1st February 2018)

• Record Type: Journal Article
• Authors: Puz, Przemyslaw; Steposz, Arkadiusz; Lasek-Bal, Anetta; Bartoszek, Karina; Radecka, Patrycja; Karuga-Pierścieńska, Aleksandra
• Is Part Of: Neurological research. Volume 40:Number 2(2018)
• Page Start: 110
• Page End: 116
• Publication Date: 2018-02-01
• Subjects: Multiple sclerosis -- atrophy -- disability assessment -- biomarkers; Neurology -- Periodicals; Neurosciences -- Periodicals; 616.8005
• DOI: 10.1080/01616412.2017.1403729
• Languages: English
• ISSNs: 0161-6412

Abstract

Abstract: The results of available studies on assessment of neurodegenerative lesions in multiple sclerosis (MS) patients using different approaches have not been conclusive. Currently, clinical assessment is the most commonly used (involving primarily mobility assessment), along with magnetic resonance imaging and electrophysiological testing. In this review we describe available clinical, neuroimaging, electrophysiological and laboratory tests used to assess the neurodegeneration in MS. Laboratory markers to determine the risk of disease, its conversion and prognosis in MS patients are being constantly sought. Cerebrospinal fluid (CSF) sample collection is invasive and constitutes a burden to a patient, so serum biomarkers are being investigated. Optimistic preliminary results of studies assessing neurofilament light chains (NFL) in serum of MS patients, encourage further research. The possibility to use such marker (or a group of markers) would significantly facilitate clinical decisions at the stage of diagnosis and treatment. Currently used treatments have limited efficacy and are associated with numerous adverse effects. Additional information from available clinical, imaging, electrophysiological or laboratory biomarker or a group of biomarkers, which predict the course and prognosis, will facilitate choosing optimal treatment and its escalation at the relevant stage. Conclusion: Using the diagnostic panel consisting of imaging, neurophysiology and serology testing along with clinical and neuropsychological assessment may improve the reliability of diagnostic instruments evaluating cerebral atrophy in MS patients.